Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Helen Jane Szekeres is active.

Publication


Featured researches published by Helen Jane Szekeres.


Xenobiotica | 2006

Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA α5-subtype inverse agonist

O'Connor D; Philip Jones; Mark Stuart Chambers; Robert James Maxey; Helen Jane Szekeres; Nicola Szeto; Scott-Stevens P; Angus Murray Macleod; Matthew P. Braun; Brian P. Cato

(3-Tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)pyrazolo[1,5-d] [1,2,4]triazine was recently identified as a functionally selective, inverse agonist at the benzodiazepine site of GABAA α5-containing receptors, which enhances performance in animal models of cognition. The routes of metabolism of this compound in rat, dog, rhesus monkey and human in vitro systems, and in vivo in rat, dog and rhesus monkey have been characterized. The current study demonstrates that both a cytosolic oxidative reaction and cytochrome P450 play important roles in the metabolism of the compound. Chemical inhibition studies showed the oxidation in human cytosol to be catalysed predominantly by aldehyde oxidase rather than the related enzyme, xanthine oxidase. The aldehyde oxidase-mediated metabolites were present in vitro and in vivo in both rat and rhesus monkey, and also in vitro in man. They were absent both in vitro and in vivo in dog.


Archive | 2002

Imidazo-pyrimidine derivatives as ligands for gaba receptors

Mark Stuart Chambers; Simon Charles Goodacre; David James Hallett; Andrew Jennings; Philip Jones; Richard T. Lewis; Kevin William Moore; Michael Geoffrey Neil Russell; Leslie J. Street; Helen Jane Szekeres


Archive | 2004

Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease

Michela Bettati; Mark Stuart Chambers; Peter Hunt; Philip Jones; Angus Murray Macleod; Helen Jane Szekeres; Martin Richard Teall


Archive | 2002

Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands

Michela Bettati; Mark Stuart Chambers; Alexander Charles Humphries; Philip Irbm Jones; Richard Thomas Lewis; Robert James Maxey; Helen Jane Szekeres; Martin Richard Teall


Bioorganic & Medicinal Chemistry Letters | 2006

Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABAA α5 inverse agonist for cognitive dysfunction

Philip Jones; John R. Atack; Matthew P. Braun; Brian P. Cato; Mark Stuart Chambers; Desmond O’Connor; Susan M. Cook; Sarah Christine Hobbs; Robert James Maxey; Helen Jane Szekeres; Nicola Szeto; Keith A. Wafford; Angus Murray Macleod


Bioorganic & Medicinal Chemistry Letters | 2004

3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the benzodiazepine site of α5-containing GABAA receptors

Helen Jane Szekeres; John R. Atack; Mark Stuart Chambers; Susan M. Cook; Alison Macaulay; Gopalan V. Pillai; Angus Murray Macleod


Archive | 2001

Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition

Mark Stuart Chambers; Philip Jones; Angus Murray Macleod; Robert James Maxey; Helen Jane Szekeres


Archive | 2006

N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists

Mark Stuart Chambers; Philip Jones; Helen Jane Szekeres


Archive | 2004

Novel 1, 3-disubstituted azetidine deivatives for use as 5ht2a receptor ligands

Mark Stuart Chambers; Neil Roy Curtis; Angus Murray Macleod; Robert James Maxey; Helen Jane Szekeres


Archive | 2004

5-HT2A receptor ligands

Mark Stuart Chambers; Neil Roy Curtis; Angus Murray Macleod; Robert James Maxey; Helen Jane Szekeres

Collaboration


Dive into the Helen Jane Szekeres's collaboration.

Researchain Logo
Decentralizing Knowledge